



DATE: August 18, 2004

SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO. 7098.US.P1	SERIAL NO. 10/721,031
	APPLICANT(S) Robert Parsons, et al.	
	FILING DATE 11/24/2003	GROUP 1

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
CL	A1	5,358,691	10/25/94	Clark, et al.	422	64	
CL	A2	6,376,207	4/23/02	Mischak, et al.	435	7.94	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CL	C1	Motwani, et al., "Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infraction". The Lancet, 341: 1109-1113, (1997).
CL	C2	Cataliotti, et al., "Circulating Natriuretic Peptide Concentrations in Patients With End-Stage Renal Disease: Role of Brain Natriuretic Peptide as a Biomaker for Ventricular Remodeling". Mayo Foundation for Medical Education and Research, 76: 1111-1119, (2001).
CL	C3	Mukoyama, et al., "Brain Natriuretic Peptide as a Novel Cardiac Hormone in Humans." Journal Clinical Investigation, 87: 11402-11412, (1991).
CL	C4	Yandle, T.G., "MINISYMPOSIUM: THE NATRIURETIC PEPTIDE HORMONES; Biochemistry of natriuretic peptides", Journal of Internal Medicine." 235: 561-576, (1994).
CL	C5	Murdoch, et al., "Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice". Heart 1997; 78:594-597.
CL	C6	Davidson et al., " Brain natriuretic peptide". Journal of Hypertension, 1994; 12:329-336.
CL	C7	Yoshiyoshi, et al., "Increased Plasma Levels of Brain Natriuretic Peptide in Hypertrophic Cardiomyopathy". The New England Journal of Medicine, 1993; Vol. 32, No. 6, pp. 433-435.
CL	C8	Shimizu, et al., "Molecular forms of human brain natriuretic peptide in plasma". Clinica Chimica Acta, 2002; 129 - 135.

EXAMINER 	DATE CONSIDERED 12/02/
--------------	---------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

Sheet 1 of 1Form PTO-1449
(REV. 8-83)US Dept. of Commerce
PATENT & TRADEMARK OFFICEATTY DOCKET NO.
118048APPLICATION NO.
10/731,031

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Yuki SASAKI et al.FILING DATE
December 10, 2003GROUP
1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	Translation	CLASS	SUB CLASS
CC-	1	JP A 10-338616	12/22/98	JAPAN	NO		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER

DATE CONSIDERED

12/04

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: August 25, 2004